NotizieAssistito da IA

Kenan Thompson Teams Up with Phathom to Tackle GERD—With a Side of Comedy

Kenan Thompson partners with Phathom to raise GERD awareness, sharing his journey with heartburn relief.

Mrudula Kulkarni
Di Mrudula Kulkarni
Caporedattore - Pharma Now
31 mar 2025Updated Jun 26, 2025 · 2 min di lettura
Kenan Thompson Teams Up with Phathom to Tackle GERD—With a Side of Comedy
freepik.com
Giornalismo assistito da IA
Reviewed by Mrudula Kulkarni, Caporedattore - Pharma Now

Kenan Thompson, the beloved comedian and longest-running cast member of Saturday Night Live, is taking on a new role—raising awareness for GERD (gastroesophageal reflux disease). Partnering with Phathom Pharmaceuticals, Thompson is sharing his personal journey with persistent heartburn through the GERD IS NO JOKE campaign. After struggling with discomfort that affected his diet, sleep, and even voice, Thompson found relief with VOQUEZNA® (vonoprazan), the first and only treatment of its kind approved by the FDA. Through humor and candid storytelling, he hopes to encourage others to talk to their doctors about effective treatment options.

As part of the campaign, Thompson is bringing his signature wit to a "Kick Some Acid Cooking Show," a lighthearted take on his GERD experience. The initiative includes a national TV and digital campaign featuring commercials on Prime Video, Hulu, and Peacock, as well as content in doctor’s office waiting rooms. Phathom Pharmaceuticals is thrilled to collaborate with Thompson, recognizing his ability to connect with audiences in an authentic way. By blending education with entertainment, the campaign aims to empower millions suffering from chronic heartburn to seek solutions that truly work.

ArgomentiNotizie
Mrudula Kulkarni
Written by
Mrudula Kulkarni
Caporedattore - Pharma Now

My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.



Discussion

Caricamento della discussione…

Altro da Pharma News

Tutti gli articoli →